Cramer spoke with Joe Herring, CEO and chairman of Covance (CVD) about his company’s prospects. Herring explained that Big Pharma companies are actively looking to lower costs and Covance is just the company to help them get it done. Herring also mentioned that Covance’s development process is two to three times faster than the company’s which it serves. He pointed out that Covance can save Big Pharma companies as much as 20% by helping them manage their clinical trials and get their drugs in front of the FDA for approval faster. “When we do this work, they’re freed up to focus on more value-add activities in other parts of their companies,” Herring said. Cramer thinks CVD could make investors some big money as long as the FDA approval process continues to run up costs for Big Pharma. Join the fastest growing community of small cap investors at Stockhideout.com